Urogyn B.V. is very pleased to announce that the Company has been acquired by Arteface Medical Investment limited (AMI) a Hong Kong based investment company.
AMI acquired the entire share capital of Urogyn.

Urogyn has developed unique products in the field of incontinence and sterilization. It’s top product Urolastic™ is a strong candidate to become the first choice in treatment of female stress urinary incontinence while Ovalastic™ is the only safe product in the world for hysteroscopic sterilization.

The acquisition by AMI will allow Urogyn to further expand its sales in Europe and South East Asia says Noes de Vries CEO of Urogyn. It furthermore will open up the way to register our products in the USA.

About Urogyn: Urogyn was founded in 2009 with the ambition of developing new products in the field of urology and gynaecology, based upon a two-component polymer technology. More products are expected to be commercially launched in the near future a.o. for treating faecal incontinence (www.urogynbv.com).